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Abstract 31 
Neurodegenerative disorders are associated with impaired cognitive function and worse 32 
physical health outcomes. This study aims to test whether polygenic risk for Alzheimer’s 33 
disease, Amyotrophic Lateral Sclerosis (ALS), or frontotemporal dementia (FTD) is 34 
associated with cognitive function and physical health in the UK Biobank, a cohort of healthy 35 
individuals.  Group-based analyses were then performed to compare the top and bottom 10% 36 
for the three neurodegenerative polygenic risk scores; these groups were compared on the 37 
cognitive and physical health variables. Higher polygenic risk for AD, ALS, and FTD was 38 
associated with lower cognitive performance. Higher polygenic risk for FTD was also 39 
associated with increased forced expiratory volume in 1s and peak expiratory flow. A 40 
significant group difference was observed on the symbol digit substitution task between 41 
individuals with high polygenic risk for FTD and high polygenic risk for ALS. The results 42 
suggest some overlap between polygenic risk for neurodegenerative disorders, cognitive 43 
function and physical health.  44 
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Introduction 45 
Alzheimer’s disease (AD) is the most common form of dementia and it is expected that over 46 
one million people in the UK will be diagnosed with this disease by 2025 [1]. Approximately 47 
10% of individuals over the age of 65 have AD, increasing in prevalence with age [2]. 48 
Pathological features of AD include amyloid B-plaques and neurofibrillary tangles [3], while 49 
degeneration of subcortical hippocampal regions and the medial temporal lobes is associated 50 
with the salient presenting memory impairment [4, 5].   51 
 52 
Frontotemporal dementia (FTD), distinct from AD, is marked by degeneration of the frontal 53 
and anterior temporal lobes. FTD is the second most prevalent presentation of early onset 54 
dementia, accounting for approximately 3-26% of cases [6]. Behavioural variant FTD is the 55 
most common phenotype, and is defined by behaviour change and executive dysfunction (e.g., 56 
impairments in working memory, cognitive flexibility, response generation, and social 57 
cognition), with relative sparing of episodic memory and visuospatial skills [7]. FTD shares 58 
genetic, pathological, and neuropsychological overlap with Amyotrophic Lateral Sclerosis 59 
(ALS). ALS is a neurodegenerative disease marked by progressive loss of motor neurons in 60 
the brain and spinal cord, resulting in muscle wasting, spasticity, and death usually due to 61 
respiratory failure within three years [8]. Approximately 35% of ALS patients will present with 62 
mild cognitive and/or behavioural changes, of a similar nature to those seen in FTD, with an 63 
additional 15% meeting diagnostic criteria for both ALS and FTD [9]. Similarly, approximately 64 
40% of FTD patients present with motor symptoms, and 15% meet ALS classification criteria 65 
[10].  66 
 67 
The genetic aetiology of AD and FTD/ALS is heterogeneous. The APOE e4 allele is the 68 
strongest risk factor for late onset AD; however, numerous additional candidate and 69 
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susceptibility loci have been established in recent years [11]. It has been suggested that late 70 
onset AD is due to susceptibility at multiple loci, and due to genetic and environmental 71 
interactions [12]. Conversely, early onset AD is autosomal dominant, accounting for 72 
approximately 1-5% of all cases, has been linked to variants in the APP, PSEN1, and PSEN2 73 
genes [13]. Autosomal dominant ALS accounts for approximately 5-10% of cases, with 85-74 
90% of cases having no strong genetic linkage [14]. Familial ALS has been linked to the SOD1, 75 
TARDBP, FUS, and more recently NEK1 genes [15, 16]. FTD shows a positive family history 76 
in up to 40% of cases, with mutations in the MAPT and GRN genes being amongst the most 77 
common [17]. The C9ORF72 mutation has been most frequently associated with familial ALS 78 
and FTD [18, 19] but can also be found in sporadic forms of both diseases [20, 21], however 79 
the cause here is often unknown, and possibly due to environmental-genetic linkages [15]. A 80 
genome-wide association study (GWAS) of FTD [22] demonstrated that the C9ORF72 81 
mutation mainly associates with the ALS-FTD variant indicating a strong genetic overlap.  82 
   83 
In addition to the genetic complexity, the cognitive profiles of AD and FTD/ALS are 84 
heterogeneous, in that impairments in executive functions, language, visuospatial skills, and 85 
memory have been recorded in all three diseases [23]. Whereas evidence does exist that 86 
memory, visuospatial, and particularly language functions may be affected in FTD, the extent 87 
to which executive dysfunction explains these observations remains unclear [24, 25]. Previous 88 
research has suggested a preclinical phase of reduced cognitive functioning for older adults 89 
who subsequently develop AD [26] and for those at genetic risk of developing AD [27-31], 90 
with similar findings reported for FTD [32, 33]. Yet, not all those at genetic risk of developing 91 
AD or FTD/ALS go on to develop the disease, and these findings may suggest that genetic 92 
carriers may be at risk of developing preclinical symptoms without necessarily developing the 93 
disease itself. Furthermore, the genetic aetiology of AD, ALS, and FTD is multifactorial, and 94 
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a significant proportion of genetic variance remains unexplained (that is, there is missing 95 
heritability [34]).  96 
 97 
As such, polygenic risk scores are becoming increasingly useful in the study of genetically 98 
complex diseases. Polygenic risk scores are valuable in aggregating genetic markers that on 99 
their own do not reach significance [35]. Higher polygenic risk for AD, based on genome-wide 100 
significant single nucleotide polymorphisms (SNPs) [36] and all common SNPs [37], has been 101 
associated with lower general cognitive ability and memory. Some research has suggested that 102 
healthy adults with a high polygenic risk for AD possess reduced brain cortical thickness [38]. 103 
Polygenic risk has been associated with cognitive performance in other diseases; for instance, 104 
a high polygenic risk of schizophrenia has been associated with a greater decline in cognitive 105 
functioning between childhood and older age [39], and reduced neural efficiency [40]. 106 
Similarly, high polygenic risk for autism has been associated with better cognitive ability in 107 
the general population [37, 41]. To date however, no identifiable research has explored whether 108 
polygenic risk for FTD or ALS is associated with cognitive, muscle, or respiratory function.  109 
 110 
As such, the aim of this study is to extend the work accomplished in AD to FTD/ALS, and to 111 
further explore whether polygenic risk for AD, FTD, or ALS is associated with cognitive 112 
performance, or with physical function measures known to be affected by motor neuron 113 
degeneration.  114 
  115 
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Materials and methods 116 
Sample 117 
This study includes baseline data and data from a web-based cognitive follow-up from the UK 118 
Biobank study, a large resource for identifying determinants of human diseases in middle aged 119 
and older healthy individuals (http://www.ukbiobank.ac.uk) [42]. A total 502,655 community-120 
dwelling participants aged between 37 and 73 years were recruited between 2006 and 2010 in 121 
the United Kingdom, and underwent extensive baseline testing including cognitive and 122 
physical assessments. All participants provided blood, urine and saliva samples for future 123 
analysis. For the follow up testing, participants completed cognitive tests remotely via a web-124 
based assessment.  125 
 126 
Measures 127 
Cognitive measures 128 
Cognitive ability was measured using five different cognitive tests. These included tests of 129 
verbal-numerical reasoning (n = 36,035), reaction time (n = 111,484), memory (n = 112,067), 130 
trail making (part A: n = 23,822, part B: n= 23,812), and symbol digit substitution (n = 26,913). 131 
The verbal-numerical reasoning test consisted of a 13-item questionnaire assessing verbal and 132 
arithmetical deduction (Cronbach α reliability of 0.62). Reaction time was measured using a 133 
computerized ‘Snap game’, during which participants were asked to press a button as quickly 134 
as possible when two cards on the screen were matching. There were eight trials, four had 135 
matching cards and required the button to be pressed (Cronbach α reliability of 0.85).  Memory 136 
was measured using a pairs matching test, where participants were asked to memorize positions 137 
of matching pairs of cards, shown for 5s on a 3 by 4 grid. All cards were then placed face down 138 
and the participant had to identify the positions of the matching pairs as quickly as possible. 139 
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The number of errors in this task was used as the (inverse) measure of memory ability. These 140 
tests have been previously described in more detail by Hagenaars et al. (2016)[37]. Executive 141 
functioning was measured using the trail making test parts A (TMT A) and B (TMT B), which 142 
were part of the follow up testing wave in UK Biobank, between 2014 and 2015. For TMT A, 143 
participants were instructed to connect numbers consecutively (which were quasi-randomly 144 
distributed on the touchscreen) as quickly as possible in ascending order by selecting the next 145 
number. TMT B is similar, but in this case letters and numbers had to be selected in alternating 146 
ascending order, e.g. 1 A 2 B 3 C etc. The difference between the raw scores for TMT A and 147 
TMT B was computed as TMT B minus TMT A (TMT B-A). Owing to positively skewed 148 
distributions, both TMT A and TMT B scores were log-transformed prior to further analyses. 149 
Further detail on these tests in UK Biobank has been published previously [43]. Processing 150 
speed was measured using the symbol digit substitution test, similar to the well-validated 151 
Symbol Digits Modalities Test [44], which was also part of the follow up testing wave. In the 152 
UK Biobank symbol digit substitution test, participants are presented with symbols paired with 153 
digits and are asked to enter the digits that are paired with the symbols in the empty spaces. 154 
The score for processing speed was based on the number of correctly matched symbols. 155 
Participants who scored 0 (n = 61) or above 40 (n = 3) were removed from further analyses, as 156 
they scored more than 4 SD away from the mean. 157 
 158 
Physical measures 159 
Muscle weakening and respiratory dysfunction are physical symptoms characteristic of ALS 160 
and in a proportion of FTD patients. Muscle strength was measured via hand grip strength for 161 
both the right and left hand, using a Jamar J00105 hydraulic hand dynamometer. Participants 162 
were seated upright in a chair with their forearms on the armrests, and were asked to squeeze 163 
the handle of the dynamometer as strongly as possible for three seconds. The maximum grip 164 
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strength for each hand was measured in whole kilogram force units. This study used maximum 165 
grip strength based on the dominant hand, as indicated by the participant.  166 
 167 
Lung (respiratory) function was assessed using a Vitalograph Pneumotract 6800 spirometer. 168 
Participants were asked to record two to three blows, lasting for at least 6 seconds, within a 169 
period of 6 minutes. The following outcomes measures were calculated by the computer: forced 170 
expiratory volume in 1s (FEV1), forced vital capacity (FVC), and peak expiratory flow (PEF). 171 
FEV1 is the amount of air, in litres, that is forcibly exhaled in 1 second following full 172 
inspiration. FVC is the amount of air, in litres, that is exhaled followed full inspiration. PEF is 173 
the maximum speed of exhalation following full inspiration. All three measures were 174 
standardized and individuals with a Z-score > 4 were excluded from FEV1 (n = 47), FVC (n = 175 
73), and PEF (n = 28). 176 
 177 
Genotyping and quality control 178 
The interim release of UK Biobank included genotype data for 152,729 individuals, of whom 179 
49,979 were genotyped using the UK BiLEVE array and 102,750 using the UK Biobank axiom 180 
array. These arrays have over 95% content in common. Quality control was performed by 181 
Affymetrix, the Wellcome Trust Centre for Human Genetics, and by the present authors; this 182 
included removal of participants based on missingness, relatedness, gender mismatch, and non-183 
British ancestry. We only included individuals of White British ancestry to reduce population 184 
stratification and the other ethnic groups were underpowered on their own to detect effects. 185 
British ancestry was defined as individuals who both self-identified as White British and were 186 
confirmed as ancestrally White British using principal components analyses (PCA) of genome-187 
wide genetic information, this information was provided by UK Biobank.  Further details have 188 
been published elsewhere [37, 45]. Variants with a minor allele frequency of less than 0.01 and 189 
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non-autosomal variants were excluded from further analysis. A sample of 112,151 individuals 190 
available for further analysis remained after quality control. 191 
 192 
Polygenic risk scores 193 
The UK Biobank genotyping data required recoding from numeric (1, 2) allele coding to 194 
standard ACGT format before being used in polygenic profile scoring analyses, this was done 195 
using a bespoke program [37]. Polygenic risk scores were created for AD [11], ALS [21], FTD, 196 
[22] in all genotyped participants using PRSice software [46]. PRSice calculates the sum of 197 
alleles associated with the phenotype of interest across many genetic loci, weighted by their 198 
effect sizes estimated from a GWAS of the corresponding phenotype in an independent sample. 199 
The GWAS summary statistics for AD, ALS, and FTD were used as the training (base) dataset, 200 
while UK Biobank was used as the prediction (target) dataset. Clumping was used to obtain 201 
SNPs in linkage disequilibrium with an r2 < 0.25 within a 250kb window. Five polygenic risk 202 
scores were then created for the three phenotypes (AD, ALS, FTD) containing SNPs selected 203 
according to the significance of their association with the phenotype, at thresholds of p < 0.01, 204 
p < 0.05, p < 0.1, p < 0.5, and all SNPs. Polygenic risk scores were also created for AD 205 
excluding SNPs within a 500 kb window of apolipoprotein E (APOE) gene. 206 
 207 
Statistical analysis 208 
All statistical analyses were performed in R version 3.4.0 [47]. The associations between the 209 
polygenic profiles and the target phenotype were examined in regression models, adjusting for 210 
age at measurement, sex, genotyping batch and array, assessment centre, and the first 10 211 
genetic principal components to adjust for population stratification. The models including 212 
measures of lung function (FEV1, FVC, PEF) were also adjusted for smoking status and height, 213 
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whereas the models for grip strength were additionally adjusted for height and weight. All 214 
models were corrected for multiple testing using the false discovery rate method [48].  215 
 216 
Following calculation of each participant’s polygenic risk score at each of the above-mentioned 217 
thresholds, participants were classified in terms of their high or low polygenic risk for each 218 
neurodegenerative disease (AD, ALS and FTD). High risk was defined by the participant’s 219 
polygenic risk score falling within the top 10th percentile and low risk was defined by the 220 
participant’s polygenic risk score falling within the bottom 10th percentile for any of the 221 
neurodegenerative diseases. These participants were then grouped based on High Risk for AD 222 
(top 10th percentile for AD and bottom 10th percentiles for ALS and FTD), High Risk for ALS 223 
(top 10th percentile for ALS and bottom 10th percentiles for AD and FTD) and High Risk for 224 
FTD (top 10th percentile for FTD and bottom 10th percentiles for ALS and AD) to homogenise 225 
pure polygenic risk for each neurodegenerative disease in these groups. There were no 226 
overlapping participants in each of these groups. These High Risk for AD, High Risk for ALS 227 
and High Risk for FTD groups were compared on cognitive and physical variables (chosen 228 
based on significant polygenic profile-target phenotype regression models from the previous 229 
analysis). Shapiro-Wilk tests were used to assess normality of the data, following which group 230 
comparisons were performed either using Kruskal-Wallis H or ANOVA tests on cognitive and 231 
physical variables, applying a Holm-Bonferroni correction. Significant Kruskal-Wallis H or 232 
ANOVA results were followed up with post hoc tests (Mann Whitney U tests, or Tukey's 233 
Honest Significant Differences, respectively), where effect size was estimated using Cohen’s 234 
d. 235 
  236 
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Results 237 
For the present study, genome-wide genotyping data was available for 112,151 individuals 238 
(58,914 females), aged between 40 and 70 years (mean age = 56.9 years, SD = 7.93) after the 239 
quality control process. Table 1 shows descriptive statistics for each of the measures used in 240 
this study.  241 
 242 
Table 1. Descriptive statistics for cognitive and physical function measures in UK 243 
Biobank. 244 
 N mean (SD)  
Baseline cognitive tests  
Verbal-numerical reasoning 36,035 6.16 (2.10) 
Reaction time (time in ms) 111,483 555.10 (112.62) 
Memory (errors) 112,067 4.06 (3.02) 
Follow-up cognitive tests  
Symbol digit substitution (correct matches) 26,913 19.74 (5.13) 
Trail making part A (time in s) 23,822 39.11 (14.73) 
Trail making part B (time in s) 23,812 66.44 (24.89) 
Trail making part B – part A (time in s) 23,769 27.22 (18.89) 
Physical function  
Grip strength (in kg) 111,735 32.17 (11.35) 
Forced expiratory volume in 1s (in litres) 104,722 2.79 (0.81) 
Peak expiratory volume (in litres/min) 104,741 389.20 (135.42) 
Forced vital capacity (in litres) 104,696 3.71 (1.01) 
Demographics   
Age at baseline (in years) 112,151 56.91 (7.93) 
Age at follow-up (in years) 27,429 63.00 (7.61) 
Gender, female N (%) 112,151 58,914 (52.53) 
College degree obtained, yes (%) 112,151 33,852 (30.20) 
 245 
Polygenic risk analysis 246 
The results for the polygenic risk analyses examining if polygenic risk for neurodegenerative 247 
diseases is associated with cognitive ability and physical health, using the best threshold 248 
(largest β), are shown in Table 2 and Fig 1. Full results including all five thresholds can be 249 
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found in S1 Table. Polygenic risk scores for AD significantly predicted verbal-numerical 250 
reasoning (β = -0.023, p = 1.27 × 10−5) [37], memory (β = 0.011, p = 0.0001) [37], symbol digit 251 
substitution (β = -0.015, p = 0.0065), and TMT B (β = 0.017, p = 0.0047). Thus, individuals 252 
with higher polygenic risk for AD answered fewer verbal-numerical reasoning questions 253 
correctly, made more errors on the memory task, completed fewer items on the symbol digit 254 
substitution test, and took longer to complete TMT B. When excluding APOE from the AD 255 
polygenic risk score, the associations with symbol digit substitution attenuated to non-256 
significance (S1 Table). Polygenic risk scores for ALS significantly predicted verbal-numerical 257 
reasoning (β = -0.019, p = 0.0004). Individuals with higher polygenic risk for ALS had lower 258 
scores on verbal-numerical reasoning. Polygenic risk scores for FTD significantly predicted 259 
TMT B (β = 0.017, p = 0.0041), FEV1 (β = 0.007, p = 0.0012), and PEF (β = 0.011, p = 4.77 260 
× 10−6). Those with higher polygenic risk for FTD took longer to complete TMT B and had 261 
higher FEV1 and PEF scores. The associations between all scores at each threshold are shown 262 
in S2 Table. 263 
  264 
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Table 2. Associations between polygenic risk scores for Alzheimer’s disease (FDR p-value ≤ 0.018), amyotrophic lateral sclerosis (FDR 265 
p-value ≤ 0.0024), and frontotemporal dementia (FDR p-value ≤ 0.0041), and cognitive and physical measures controlling for age, sex, 266 
assessment centre, genotyping batch and array and 10 genetic principal components for population structure. pT, polygenic risk score 267 
threshold for best model; *, previously published by Hagenaars et al., (2016) [37] 268 
 Alzheimer's disease  Amyotrophic lateral sclerosis Frontotemporal dementia  
  pT β p pT β p pT β p 
Verbal-numerical reasoning 0.05 -0.0229 1.27 × 10−5* 0.05 -0.0188 0.0004 1 -0.0085 0.1036 
Reaction time 0.5 0.0052 0.0700* 1 0.0023 0.4315 0.5 -0.0033 0.2489 
Memory 0.1 0.0114 0.0001* 0.1 0.0080 0.0074 0.05 0.0053 0.0737 
Symbol digit substitution 0.5 -0.0150 0.0065 0.01 -0.0063 0.2613 0.01 -0.0053 0.3316 
Trail making part A 0.05 0.0144 0.0195 0.01 0.0087 0.1609 0.1 0.0104 0.0900 
Trail making part B 0.5 0.0168 0.0047 0.1 0.0155 0.0101 0.1 0.0171 0.0041 
Trail making part B-A 1 0.0104 0.0965 0.1 0.0166 0.0091 0.1 0.0093 0.1410 
Grip strength 0.1 -0.0016 0.3963 0.01 0.0032 0.0997 0.05 0.0020 0.2911 
Forced expiratory volume in 1s 1 -0.0027 0.2018 0.01 0.0022 0.3066 0.05 0.0068 0.0012 
Peak expiratory flow 1 -0.0039 0.1159 0.01 0.0017 0.4943 0.1 0.0113 4.77 × 10−6 
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Forced vital capacity 1 -0.0014 0.4817 0.01 0.0019 0.3158 0.05 0.0027 0.1628 
269 
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Fig 1. Heat map of associations between the polygenic profile scores for 270 
neurodegenerative disease and cognitive ability and physical health. Stronger associations 271 
are indicated by darker shades, red indicates a positive association, blue indicates a negative 272 
association. AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; FTD, 273 
frontotemporal dementia; TMT B-A, trail-making part B – part A; TMT B, trail making part 274 
B; TMT A, trail making part A; DSS, digit symbol substitution; VNR, verbal numerical 275 
reasoning; FVC, forced vital capacity; PEF, peak expiratory flow; FEV1, forced expiratory 276 
volume in 1s. *, significant association after FDR correction (p-value ≤ 0.018 (AD), 0.024 277 
(ALS), or 0.0041 (FTD)).  Full results can be found in S1 Table. 278 
 279 
Polygenic Inter-group Comparison 280 
Table 3 shows the comparison of polygenic risk groups on cognitive and physical variables. 281 
There was no significant difference between those categorised as having high polygenic risk 282 
for AD, ALS, or FTD on age or gender distribution. The only significant difference between 283 
these groups was observed with one of the cognitive variables, specifically, symbol digit 284 
substitution task. Follow up, post hoc analysis showed that participants with a high polygenic 285 
risk for FTD performed significantly worse on the symbol digit substitution task when 286 
compared to participants with a high polygenic risk for ALS (U = 396, p < 0.01, d = 0.85). 287 
No significant differences were observed between other groups on cognitive and physical 288 
variables. 289 
  290 
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Table 3. Cognitive and physical variable comparison between high Alzheimer’s disease 291 
(AD) polygenic risk, amyotrophic lateral sclerosis (ALS) polygenic risk, and 292 
frontotemporal dementia (FTD) polygenic risk, N for each group is shown. 293 
 High Risk AD High Risk 
ALS 
High Risk 
FTD 
p-
value 
Age 56.93 ± 7.81 
(n = 389) 
57.24 ± 7.75 
(n = 386) 
57.07 ± 7.95 
(n = 343) 
0.86 
Gender (M/F) 179/210 188/198 157/186 0.67 
Cognitive     
 Trail making part B‡  4.10 ± 0.34 
(n = 27) 
4.05 ± 0.40 
(n = 25) 
4.15 ± 0.24 
(n = 17) 
1.00† 
 Verbal-numerical 
reasoning 
6.50 ± 2.40 
(n = 28) 
6.22 ± 1.91 
(n = 40) 
6.42 ± 2.02 
(n = 24) 
1.00† 
 Memory 4.12 ± 3.26 
(n = 107) 
4.09 ± 2.98 
(n = 112) 
3.72 ± 2.73 
(n = 103) 
1.00† 
 Symbol digit substitution 19.77 ± 5.59 
(n = 30) 
22.16 ± 5.47 
(n = 25) 
17.57 ± 5.34 
(n = 21) 
0.04† 
Physical     
 FEV1 2.78 ± 0.70 
(n = 112) 
2.84 ± 0.84 
(n = 93) 
2.66 ± 0.72 
(n = 84) 
0.62† 
 PEF 383.09 ± 
124.25 
(n = 92) 
398.06 ± 
138.79 
(n = 101) 
394.27 ± 
125.92 
(n = 96) 
0.62† 
‡Log transformed; †Kruskal-Wallis H test; Chi Squared tests used for gender distribution 294 
comparison; Mean ± Standard Deviation shown for each high neurodegenerative disease 295 
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polygenic risk group; bold text indicate significance adjusted for multiple comparisons 296 
(Holm-Bonferroni)  297 
  298 
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Discussion 299 
The present study aimed to explore whether polygenic risk for AD, FTD, or ALS is associated 300 
with cognitive performance, grip strength, or lung function measures. Using the large 301 
cognitive, physical and genotypic data available in the UK Biobank, in concordance with the 302 
most up to date GWAS consortia of neurodegenerative disease (AD, ALS and FTD), our results 303 
showed a novel relationship between cognitive and physical function variables and polygenic 304 
risk for neurodegenerative conditions in a healthy population, particularly in the case of AD.  305 
 306 
The findings of this study demonstrate that higher polygenic risk of AD is associated with 307 
numerous cognitive functions; specifically, reduced performance in verbal-numerical 308 
reasoning, memory, processing speed (symbol digit substitution), and executive functioning 309 
(TMT B). Sensitivity analysis indicated that the association between AD and cognitive ability 310 
(except symbol digit substitution) was not driven by the APOE gene. Although an association 311 
between polygenic risk of AD and cognitive ability – that is significant associations with 312 
verbal-numeric reasoning and memory - in UK Biobank have been reported previously [37], 313 
the present study extends these findings to measures of executive functioning and processing 314 
speed. Unlike AD, higher polygenic risk for ALS demonstrated only one significant 315 
relationship with cognitive function, namely verbal-numerical reasoning. Higher polygenic 316 
risk for FTD was only associated with reduced performance on the TMT B.     317 
 318 
Physical function measures used in this study were chosen based on their relevance in clinical 319 
cases of FTD and ALS, in particular, measures of grip strength and lung function. 320 
Counterintuitively higher risk of FTD was related to better respiratory functioning (FEV1 and 321 
PEF). Finally, a higher risk of ALS was not associated with grip strength or measures of lung 322 
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function. It is worth noting, however, that the amount of variance explained by the polygenic 323 
risk scores was very small (< 0.01%). As such, these finding may be spurious.  324 
 325 
In a small subset of participants, those with a high polygenic risk for FTD performed worse on 326 
a processing speed task (symbol digit substitution task) compared to those with high polygenic 327 
risk for ALS. There has been an emphasis on linkage and continuum-based relationship 328 
between ALS and FTD, this finding based on pure genetic risk could provide insight towards 329 
sub-clinical cognitive impairment. The cognitive profile of ALS largely mirrors that of FTD, 330 
albeit in a milder form. Patients with FTD have demonstrated processing speed impairments, 331 
both cross-sectionally and longitudinally [49, 50]. However, studies of cognition in ALS have 332 
largely ignored tasks of processing speed due to the confounding presence of motor impairment 333 
in this patient group. That said, current research suggests unaffected processing speed in 334 
patients with ALS. As such, previous research combined with the findings herein may suggest 335 
a future avenue for detecting FTD syndromes in patients with ALS. However, further studies 336 
are needed to explore the reliability of differences between polygenic risk of FTD and ALS, 337 
and between people diagnosed with these diseases.  338 
 339 
There are several limitations to note regarding the present study. While the cognitive tasks in 340 
the present study covered a number of domains, the measures are brief and non-standardized. 341 
As such, the sensitivity to detect small differences in cognitive ability are limited. Additionally, 342 
due to the nature of self-administration on a computer (in case of the measures for the symbol 343 
digit substitution test and the trail making test), the environment under which the tasks are 344 
performed could not be fully standardised. The trail making test could be confounded by the 345 
movement speed in older individuals, however subtracting completion time for TMT A from 346 
TMT B completion time (TMT B-A) will partially allow the relative contributions of 347 
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movement speed to be parsed from the more complex executive functions in TMT B. Finally, 348 
a limitation is that the polygenic inter-group comparison yielded smaller sample sizes, which 349 
could be indicative of the rarity of ‘pure’ polygenic risk for each disease in healthy adults. The 350 
results in this area should therefore be interpreted with caution and require larger scale 351 
replication, despite building on previous research of a smaller sample size [49, 50]. 352 
 353 
Furthermore, while it is interesting to speculate how the findings of the present study may relate 354 
to those individuals who actually have AD, FTD, or ALS, it is important to remember that the 355 
participants of this study were healthy individuals. Those described as high polygenic risk for 356 
a particular disease are only at higher risk when compared to other participants of this study. It 357 
would be incorrect to describe these individuals as being at a high risk of developing a 358 
neurodegenerative disease more generally.   359 
 360 
Future research may explore whether these findings replicate given more extensive and 361 
controlled measures of cognitive functioning. Provided that FTD is primarily a disease marked 362 
by changes in behaviour, the inclusion of such measures would be informative. Additionally, 363 
as previous research has suggested that reduction of cortical thickness was associated with 364 
polygenic risk for AD in healthy adults [38], it would be informative to further explore the 365 
neural correlates of polygenic risk for different neurodegenerative disorders (e.g. ALS and 366 
FTD) in this sample. 367 
 368 
Conclusion 369 
The present study confirmed and extended previous findings that polygenic risk for AD is 370 
associated with multi-domain cognitive functioning in healthy adults. Additionally, the 371 
findings of this study demonstrate that polygenic risk for ALS is associated with verbal-372 
 21 
 
numeric reasoning, while polygenic risk for FTD was associated with executive functioning. 373 
Physical function measures commonly affected in patients with ALS, were not associated with 374 
polygenic risk of ALS in healthy adults. However, higher polygenic risk significantly predicted 375 
better lung function.  376 
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